A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 827 in Subjects With Rheumatoid Arthritis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Brodalumab (Primary) ; Brodalumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 24 Nov 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
    • 24 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top